Medable Inc. has announced the first stage of its European expansion plans with a new EMEA headquarters in Dublin. The regional headquarters will serve as a hub for expanded sales, customer success and software development in Europe. Medable’s European expansion is designed to enable greater engagement with hundreds of pharma, biotech and medical device companies across the UK, Germany, Switzerland, Spain, and Benelux.
Medable has an existing presence in Europe with roughly 60 employees and contractors currently based in the UK, Germany, Denmark, and various other locations in Central and Eastern Europe. The company intends to hire up to 50 positions in Dublin over the next three years, as part of its extensive growth across Europe in coming years.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.